These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12692522)

  • 1. Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells.
    Müller L; Knights A; Pawelec G
    Hematol J; 2003; 4(1):57-66. PubMed ID: 12692522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
    Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
    Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
    Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
    Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
    Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
    Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining MHC class II T helper epitopes for WT1 tumor antigen.
    Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
    Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
    Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
    Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
    Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
    Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
    Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
    Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol.
    Knights AJ; Zaniou A; Rees RC; Pawelec G; Müller L
    Cancer Immunol Immunother; 2002 Jul; 51(5):271-81. PubMed ID: 12070714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
    Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
    J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
    Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M
    Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
    Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Nakajima H; Elisseeva OA; Harada Y; Li Z; Tatsumi N; Kamino E; Shirakata T; Nishida S; Taniguchi Y; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Dec; 52(12):591-600. PubMed ID: 19120973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
    Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
    Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.
    Bellantuono I; Gao L; Parry S; Marley S; Dazzi F; Apperley J; Goldman JM; Stauss HJ
    Blood; 2002 Nov; 100(10):3835-7. PubMed ID: 12411326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
    Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
    Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML; Afshar A; Marincola FM; Rivoltini L; Kawakami Y; Rosenberg SA
    Cancer Res; 1995 Nov; 55(21):4972-9. PubMed ID: 7585538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
    Wagner WM; Ouyang Q; Pawelec G
    Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.